Alemtuzumab Versus Thymoglobulin Induction Therapy in Kidney and Pancreas Transplantation.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 02 May 2016
At a glance
- Drugs Alemtuzumab (Primary) ; Antithymocyte globulin (Primary)
- Indications Kidney-pancreas transplant rejection; Pancreas transplant rejection; Renal transplant rejection
- Focus Adverse reactions; Therapeutic Use
- 26 Apr 2016 Planned End Date changed from 1 Jun 2015 to 1 Jun 2017.
- 23 Oct 2011 Results assessing the rates of infectious complications presented at the 49th Annual Meeting of the Infectious Diseases Society of America.
- 15 Aug 2010 Results presented at the 23rd International Congress of the Transplantation Society.